Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 501 - 550 out of 45,984

Document Document Title
WO/2014/022841
The invention provides for methods of treating lysosomal storage disorders and/or reduction of non-cholesterol lipids, using cyclodextrin compounds, including in combination with other therapeutics, including vitamin E.  
WO/2014/022143
The use of ORL-1 receptor antagonists of the formula (I) for the treatment of anxiety disorders is described.  
WO/2014/021337
The present invention provides a compound and pharmaceutical composition for a neuropsychological disorder or malignant tumor, the use thereof, and a method for preventing, improving, inhibiting the progression of and/or treating a neuro...  
WO/2014/020608
A method of treating a motor neuron disease (MND) in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of an agent capable of enhancing processing of a pre-mi RNA...  
WO/2014/021455
Provided is a medicine which can be widely used for intractable neurological disorders, inflammatory diseases, etc. This immune cell activation inhibitor is characterized in comprising bromovalerylurea or a derivative thereof. This immun...  
WO/2014/019468
Provided is a piperazinotrizole compound represented by general formula I or an isomer, a pharmaceutically acceptable salt, ester, prodrug or hydrate thereof. Also provided are a method for preparing the compound, a drug composition cont...  
WO/2014/019092
The present application relates to imidazolidinecliones, compositions comprising these compounds and their use, in particular for the treatment of diseases, disorders or conditions characterized by or associated with the hypercitrullinat...  
WO/2014/019979
The invention relates to 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalene derivatives of general formula (I) which are inhibitors of phosphodiesterase 2 and/or 10, useful in treating central nervous system diseases and other disease...  
WO/2014/021273
The morphinan derivatives represented by general formula (I) (wherein: R1 represents a cycloalkyl alkyl, an aralkyl, or the like; R2 represents an aralkyl, a heteroaryl alkyl, or the like; R3, R4 and R5 represent hydrogen, a hydroxy, or ...  
WO/2014/019855
The present invention concerns a method for preparing a creatine fatty ester or derivative thereof comprising at least one step consisting in reacting a diprotected creatinine with a molecule bearing at least one alcohol functional group...  
WO/2014/022167
The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.  
WO/2014/016267
The present invention relates to compounds of general formula (I) wherein Ar1/Ar2 are phenyl or a 5 or 6-membered heteroaryl; R1/R2 is hydrogen, halogen, lower alkyl, CF3 or lower alkoxy; n,m are 1 or 2; or to a pharmaceutically acceptab...  
WO/2014/017593
A production method for an adhesive patch comprising a supporting body layer and an adhesive layer, said production method including: a mixture preparation step in which asenapine or a pharmacologically acceptable salt thereof and a sodi...  
WO/2014/016789
A compound of the general formula (I) wherein R1 is selected from the group consisting of phenyl unsubstituted or substituted with 1 to 3 substituents selected from F, Cl, Br, I, CN, -O-C1-C3-alkyl, fluorinated -O-C1-C3-alkyl, -(CH2)mOH ...  
WO/2014/015436
The present disclosure provides for an apparatus and related method for controlling the rate of nicotine delivery into systemic circulation of a subject. The method comprises transdermally administering nicotine at a topical administrati...  
WO/2014/018570
Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit cystathionine -γ-lyase (CSE). Also described herein are methods for using such CSE inhibitors, alone or in combination with other com...  
WO/2014/017462
It is now revealed that the amount of syntenin protein is increased in tuberous sclerosis. It is now also revealed that the binding between syndecan-2 protein, which is a protein known as a factor capable of inducing the formation of spi...  
WO/2014/015993
The present invention relates to compounds of formula (I) having a bicyclic aza-amides scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together wit...  
WO/2014/018741
In certain embodiments, the disclosure relates to heterocyclic flavone derivatives, such as those described by formula provided herein, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure rela...  
WO/2014/017594
An adhesive patch comprising a supporting body layer and an adhesive layer. The adhesive layer contains asenapine and/or a pharmacologically acceptable salt thereof, isopropyl palmitate, and an adhesive base.  
WO/2014/015523
The invention relates to novel heteroaryl and heterocycle compounds and pharmaceutical compositions comprising them, uses and methods thereof for inhibiting the activity of PI3k and for treating inflammatory and autoimmune disorders dise...  
WO/2014/016003
The invention relates to the use of biotin for treating multiple sclerosis, in particular of the progressive forms and of the neurological sequelae.  
WO/2014/017569
A pharmaceutical product for lowering blood LDL, which is a pharmaceutical product that contains a compound represented by formula (I) as an active ingredient, said compound having actions of inhibiting the expression of PCSK9mRNA, lower...  
WO/2014/017243
The purpose of the present invention is to provide a sleep quality improving agent which has a satisfactory sleep quality improving effect, can exert the effect through oral administration in any dosage form, and has ensured safety to th...  
WO/2014/018563
Described herein are methods for the treatment of cancers, particularly neuroendocrine tumors. Also described herein are methods for selecting drug candidates for the treatment of cancers such as neuroendocrine tumors.  
WO/2014/018571  
WO/2014/016653
The invention provides a method of assembling a device and a kit suitable for administration to multiple patients comprising a multi-dose pharmaceutical composition of nasal analgesic in the form of a nasal spray. The present invention a...  
WO/2014/017595
A patch that is provided with a support layer and an adhesive layer, wherein said adhesive layer contains free asenapine, an alkali maleate and a rubber adhesive agent.  
WO/2014/018569
Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit cystathionine-γ- lyase (CSE). Also described herein are methods for using such CSE inhibitors, alone or in combination with other com...  
WO/2014/013313
Compounds and compositions for use as starting materials or intermediate materials in the preparation of opioids including, e.g., oxymorphone base and/or an oxymorphone salt; processes for preparing these compounds and compositions; uses...  
WO/2014/012851
The present invention relates to ethynyl derivatives of formula (I) wherein R1 is phenyl, which is optionally substituted by 1-2 halogen atoms; selected from fluorine or chlorine; or to a pharmaceutically acceptable acid addition salt in...  
WO/2014/013338
The present invention relates to the use of compounds of formula (I): wherein R1 is H, substituted or unsubstituted aryl, heteroaryl or C1-24 aliphatic group, -(CH2)1-3-aryl or -(CH2 )1-3 - heteroaryl, R2 is selected from the group consi...  
WO/2014/013469
The invention relates to compound of the formula (I) or a salt thereof, wherein the substituents are as defined in the specification; to its preparation, to its use as medicament and to medicaments comprising it.  
WO/2014/015338
A method of inhibiting, reducing, and/or treating pathological apoptosis and/or protein aggregation in a subject includes administering to the subject an amount of a therapeutic polypeptide effective to inhibit, reduce, and/or treat the ...  
WO/2014/012593
The present invention relates to the use of compounds of formula (I) wherein R1 is selected from the group consisting of C1-8alkyl; R2 is selected from the group consisting of C1-8alkyl; R3 is selected from the group consisting of H and ...  
WO/2014/015125
New salts of a fused aminodihydrothiazine derivative, and pharmaceutical uses thereof.  
WO/2014/013090
The present invention relates to a solid composite of fingolimod base and a copolymer of methacrylic acid and divinylbenzene, a pharmaceutical formulation comprising said composite and the use of either the solid composite or pharmaceuti...  
WO/2014/013076
A compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R9 are as defined in the specification and which compound has an Αβ production inhibitory effect and may be useful as a prophylactic or therapeutic ...  
WO/2014/015047
The specification provides compositions and methods to treat neurodegenerative diseases.  
WO/2014/013311
Compounds and compositions for use as starting materials or intermediate materials in the preparation of opioids including, e.g., oxycodone base and/or an oxycodone salt; processes for preparing these compounds and compositions; uses of ...  
WO/2014/013497
The invention provides fatty acid derivatives for use in a method of treatment of at least one disease, disorder or condition selected from anxiety, depression, conditions associated menopause, stress, bipolar disorder, neuropathic pain ...  
WO/2014/013258
This invention relates to stem cell microparticles, their use and production, in particular neural stem cell microparticles and their use in therapy. The stem cell microparticle is typicallyan exosome or microvesicleand may be derived fr...  
WO/2014/015247
Disclosed herein are compounds of formula (I) and therapeutic methods of treatment with compounds of formula (I), wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists us...  
WO/2014/015261
Methods for producing new neurons in the brain in vivo are provided according to aspects of the present invention which include introducing NeuroDl into a glial cell, particularly into a reactive astrocyte or NG2 cell, thereby "convertin...  
WO/2014/008629
This invention relates to novel compounds and hydrochloric acid salts thereof. More specifically, this invention relates to novel compounds and hydrochloric acid salts thereof derived from donepezil. This invention also provides composit...  
WO/2014/008648
A composition comprising reduced glutathione and acetaminophen and preparation method thereof. The main drug of the composition is 0.1%-99.9% reduced glutathione, 99.9%-1% acetaminophen. The composition can be formulated as tablets, sust...  
WO/2014/011083
The invention relates to the field of pharmaceuticals, specifically to solid pharmaceutical compositions containing 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol or a pharmaceutically acceptable salt thereof, a stabiliser, a lubrica...  
WO/2014/010732
Provided is a compound having a PDE2A selective inhibitory effect which is useful as a prophylactic/therapeutic drug for integration disorder syndrome, Alzheimer's disease and the like. Provided is a compound represented by formula (1): ...  
WO/2014/011085
The invention relates to the field of medicine. Described is an effective, low-toxicity agent in the form of the methyl 2-cyano-3,12-dioxo-18βН-olean-1(2),11(9)-dien-30-oate of formula (1): which exhibits antioxidant, anti-inflammatory...  
WO/2014/011461
The present invention provides compounds of Formula (I) as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments.  

Matches 501 - 550 out of 45,984